Your browser is no longer supported. Please, upgrade your browser.
REPL Replimune Group, Inc. daily Stock Chart
REPL [NASD]
Replimune Group, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own12.80% Shs Outstand38.82M Perf Week-0.05%
Market Cap882.90M Forward P/E- EPS next Y-2.16 Insider Trans-4.54% Shs Float34.46M Perf Month4.38%
Income-52.60M PEG- EPS next Q-0.46 Inst Own80.00% Short Float1.62% Perf Quarter75.38%
Sales- P/S- EPS this Y-15.60% Inst Trans-1.19% Short Ratio2.72 Perf Half Y34.57%
Book/sh4.73 P/B4.68 EPS next Y-11.90% ROA-27.00% Target Price29.43 Perf Year68.70%
Cash/sh4.23 P/C5.24 EPS next 5Y- ROE-33.30% 52W Range8.58 - 26.22 Perf YTD54.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.52% Beta-
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low158.16% ATR1.96
Employees122 Current Ratio14.70 Sales Q/Q- Oper. Margin- RSI (14)50.75 Volatility7.36% 8.37%
OptionableNo Debt/Eq0.20 EPS Q/Q-92.40% Profit Margin- Rel Volume0.90 Prev Close22.15
ShortableYes LT Debt/Eq0.19 Earnings- Payout- Avg Volume204.76K Price22.15
Recom1.90 SMA20-1.28% SMA506.36% SMA20039.57% Volume0 Change0.00%
Jul-01-20Downgrade H.C. Wainwright Buy → Neutral $25
May-05-20Initiated Barclays Overweight $21
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jul-12-19Upgrade JP Morgan Neutral → Overweight $27 → $26
Jul-08-19Initiated H.C. Wainwright Buy $26
Apr-25-19Initiated Wedbush Outperform $24
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Aug-14-18Initiated Leerink Partners Outperform $25
Aug-14-18Initiated JP Morgan Overweight $26
Jun-22-20 02:27PM  
Jun-17-20 08:00AM  
Jun-11-20 08:47AM  
Jun-08-20 11:21PM  
04:16PM  
Jun-03-20 07:15AM  
07:00AM  
Apr-30-20 06:00AM  
Apr-02-20 07:00AM  
Feb-13-20 07:00AM  
Feb-06-20 08:00AM  
Jan-13-20 07:00AM  
Jan-09-20 07:00AM  
Jan-07-20 08:00AM  
Dec-23-19 02:56PM  
Dec-09-19 08:00AM  
Nov-26-19 08:00AM  
Nov-22-19 12:13PM  
Nov-14-19 06:22AM  
Nov-12-19 04:06PM  
Nov-11-19 08:00AM  
Nov-08-19 07:30AM  
Oct-31-19 04:00PM  
02:19PM  
Oct-24-19 08:00AM  
Oct-15-19 07:00AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-13-19 04:39AM  
Aug-14-19 08:00AM  
Aug-06-19 08:00AM  
Jul-19-19 09:16AM  
Jun-28-19 08:00AM  
Jun-01-19 09:00AM  
May-30-19 08:00AM  
May-16-19 07:00AM  
Apr-25-19 02:23PM  
Apr-01-19 07:00AM  
Feb-14-19 08:00AM  
Feb-07-19 08:00AM  
Jan-04-19 12:33PM  
Jan-03-19 08:00AM  
Dec-20-18 08:00AM  
Dec-08-18 06:19PM  
Dec-05-18 08:00AM  
Nov-14-18 08:38AM  
08:00AM  
Sep-26-18 08:00AM  
Sep-06-18 04:01PM  
Aug-30-18 08:00AM  
Aug-14-18 02:49PM  
Jul-24-18 07:44AM  
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coffin RobertPresident & Chief R&D OfficerJul 09Sale22.13169,7503,757,2952,024,118Jul 10 09:00 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 20Sale17.0424,250413,2202,193,868Feb 24 04:02 PM
Coffin RobertPres & Chief Res & Dev OfficerFeb 12Sale17.0448,500826,1982,218,118Feb 14 04:00 PM
Esposito PamelaChief Business OfficerDec 20Option Exercise1.7525,70044,975112,700Dec 23 04:32 PM
Kaufman HowardChief Medical OfficerNov 26Option Exercise3.3058,067191,62158,067Dec 19 04:02 PM
Rhodes Jason PDirectorNov 18Buy13.611,100,00014,971,0001,100,000Nov 20 05:50 PM
Omega Fund IV, L.P.10% OwnerNov 18Buy13.61220,0002,994,2005,328,939Nov 20 12:36 PM